. 2020 Sep 15;8:e9842. doi: 10.7717/peerj.9842

Table 1. Baseline characteristics and RDN ablation parameters.

Index	Standard treatment	Intensive treatment	P
n (%)	21 (50.0)	21 (50.0)	1.00
Age, y	61.8 ± 13.3	62.7 ± 12.8	.713
Sex (male), n(%)	16 (38.1)	15 (35.7)	.726
HR (bpm, $\bar{χ} \pm s$ )	79.7 ± 10.0	82.0 ± 17.0	.612
Medical history n(%)
CAD	6 (14.4)	10 (24.0)	.170
2-DM	9 (23.8)	9 (23.8)	.622
Atrial fibrillation	3 (7.1)	0 (0.0)	.116
Hyperlipidemia	3 (7.1)	4 (9.5)	.500
Stroke	4 (9.5)	1 (2.4)	.172
Type of antihypertensive medication n(%)
RAAS Blockers	20 (48.0)	13 (31.2)	.010
β-Blocker	18 (43.2)	14 (33.6)	.139
Ca²⁺-Blocker	16 (38.4)	15 (36)	.500
Diuretics	21 (50.0)	21 (50.0)	1.00
Ambulatory BP (mm Hg, $\bar{χ} \pm s$ )
SBP	155.9 ± 23.2	168.6 ± 28.4	.107
DBP	87.4 ± 12.1	93.9 ± 14.8	.092
Ablation points $(\bar{χ} \pm s)$	6.2 ± 0.8	11.0 ± 2.0	.000
Ablation impedance (Ω, $\bar{χ} \pm s$ )
Initial	177.9 ± 26.6	190.1 ± 22.4	.115
Lowest	159.0 ± 21.9	167.2 ± 18.1	.193
Creatinine (mg/dL, $\bar{χ} \pm s$ ) $(\bar{χ} \pm s)$	102.1 ± 47.9	135.7 ± 193.5	.455
eGFR [mL/min/1.73m², $\bar{χ} \pm s$ ]	73.6 ± 24.1	71.8 ± 28.0	.829
Glucose (mg/Dl, $\bar{χ} \pm s$ )	6.5 ± 2.4	5.5 ± 2.0	.135
AST (U/L, $\bar{χ} \pm s$ )	22.2 ± 9.2	36.9 ± 15.1	.339
ALT (U/L, $\bar{χ} \pm s$ )	20.5 ± 14.32	38.6 ± 18.8	.351
Hb (g/L, $\bar{χ} \pm s$ )	133.3 ± 16.2	141.1 ± 26.5	.260
BNP (pg/mL, $\bar{χ} \pm s$ )	596.9 ± 220.2	422.3 ± 146.7	.506

Notes.

Abbreviations